Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Overexpression of human epidermal growth factor receptor (EGFR) is linked to poor prognosis in various cancers.
• EGFR amplification presents a therapeutic target in certain tumors, including rhabdomyosarcoma (RMS).
• Combination therapies involving EGFR-targeting agents and cytotoxic drugs are being explored for RMS with EGFR amplification.

Purpose of the Study:

• To investigate the efficacy of combining cetuximab (an EGFR-targeting agent) with actinomycin D in human RMS cell lines.
• To evaluate the impact of this combination on cell growth inhibition and apoptosis, particularly in EGFR-overexpressing RMS cells.

Main Methods:

• Four human RMS cell lines were utilized.
• EGFR and K-ras gene status (wild-type or overexpressed/amplified) were determined using flow cytometry, real-time PCR, and direct sequencing.
• The combination effects of cetuximab and actinomycin D on cell growth were assessed, calculating the combination index.
• Apoptosis rates were measured in EGFR-positive cells treated with the combination therapy.

Main Results:

• All four RMS cell lines possessed wild-type K-ras.
• Two of the four RMS cell lines exhibited EGFR overexpression.
• The combination of cetuximab and actinomycin D demonstrated synergistic efficacy, significantly inhibiting cell growth (combination index < 1).
• Combined treatment notably increased the rate of apoptosis in EGFR-positive RMS cells.

Conclusions:

• Cetuximab exhibits antitumor activity in EGFR-amplified RMS cells when used in combination with other antitumor agents.
• The synergistic effect observed suggests that cetuximab is a promising therapeutic candidate for RMS with EGFR amplification.
• Combination therapy with cetuximab and cytotoxic agents like actinomycin D warrants further investigation for treating EGFR-amplified RMS.